Literature DB >> 33806468

Cancer-Associated Fibroblasts as Players in Cancer Development and Progression and Their Role in Targeted Radionuclide Imaging and Therapy.

Sofia Koustoulidou1, Mark W H Hoorens1, Simone U Dalm1, Shweta Mahajan2, Reno Debets2, Yann Seimbille1, Marion de Jong1.   

Abstract

Cancer Associated Fibroblasts (CAFs) form a major component of the tumour microenvironment, they have a complex origin and execute diverse functions in tumour development and progression. As such, CAFs constitute an attractive target for novel therapeutic interventions that will aid both diagnosis and treatment of various cancers. There are, however, a few limitations in reaching successful translation of CAF targeted interventions from bench to bedside. Several approaches targeting CAFs have been investigated so far and a few CAF-targeting tracers have successfully been developed and applied. This includes tracers targeting Fibroblast Activation Protein (FAP) on CAFs. A number of FAP-targeting tracers have shown great promise in the clinic. In this review, we summarize our current knowledge of the functional heterogeneity and biology of CAFs in cancer. Moreover, we highlight the latest developments towards theranostic applications that will help tumour characterization, radioligand therapy and staging in cancers with a distinct CAF population.

Entities:  

Keywords:  CAFs; FAP; radionuclide therapy; theranostics

Year:  2021        PMID: 33806468      PMCID: PMC7961537          DOI: 10.3390/cancers13051100

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  114 in total

Review 1.  Myofibroblasts: paracrine cells important in health and disease.

Authors:  D W Powell
Journal:  Trans Am Clin Climatol Assoc       Date:  2000

2.  FAP: the next billion dollar nuclear theranostics target ?

Authors:  Jeremie Calais
Journal:  J Nucl Med       Date:  2020-01-10       Impact factor: 10.057

Review 3.  Role of the tumor microenvironment in tumor progression and the clinical applications (Review).

Authors:  Yao Yuan; Yu-Chen Jiang; Chong-Kui Sun; Qian-Ming Chen
Journal:  Oncol Rep       Date:  2016-03-07       Impact factor: 3.906

4.  Acylated Gly-(2-cyano)pyrrolidines as inhibitors of fibroblast activation protein (FAP) and the issue of FAP/prolyl oligopeptidase (PREP)-selectivity.

Authors:  Oxana Ryabtsova; Koen Jansen; Sebastiaan Van Goethem; Jurgen Joossens; Jonathan D Cheng; Anne-Marie Lambeir; Ingrid De Meester; Koen Augustyns; Pieter Van der Veken
Journal:  Bioorg Med Chem Lett       Date:  2012-04-04       Impact factor: 2.823

5.  Phase II trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancer.

Authors:  Kalyani Narra; Stefanie R Mullins; Hyung-Ok Lee; Brenda Strzemkowski-Brun; Kimberly Magalong; Victoria J Christiansen; Patrick A McKee; Brian Egleston; Steven J Cohen; Louis M Weiner; Neal J Meropol; Jonathan D Cheng
Journal:  Cancer Biol Ther       Date:  2007-08-14       Impact factor: 4.742

6.  Fibroblasts drive an immunosuppressive and growth-promoting microenvironment in breast cancer via secretion of Chitinase 3-like 1.

Authors:  N Cohen; O Shani; Y Raz; Y Sharon; D Hoffman; L Abramovitz; N Erez
Journal:  Oncogene       Date:  2017-04-03       Impact factor: 9.867

7.  An Immunoscore System Based On CD3+ And CD8+ Infiltrating Lymphocytes Densities To Predict The Outcome Of Patients With Colorectal Adenocarcinoma.

Authors:  Mouna Trabelsi; Faten Farah; Bechir Zouari; Mohamed Habib Jaafoura; Maher Kharrat
Journal:  Onco Targets Ther       Date:  2019-10-21       Impact factor: 4.147

Review 8.  Crosstalk between cancer-associated fibroblasts and immune cells in cancer.

Authors:  Yuanyuan An; Fengtian Liu; Ying Chen; Qing Yang
Journal:  J Cell Mol Med       Date:  2019-10-23       Impact factor: 5.310

9.  Epigenetic switch drives the conversion of fibroblasts into proinvasive cancer-associated fibroblasts.

Authors:  Jean Albrengues; Thomas Bertero; Eloise Grasset; Stephanie Bonan; Majdi Maiel; Isabelle Bourget; Claude Philippe; Cecilia Herraiz Serrano; Samia Benamar; Olivier Croce; Victoria Sanz-Moreno; Guerrino Meneguzzi; Chloe C Feral; Gael Cristofari; Cedric Gaggioli
Journal:  Nat Commun       Date:  2015-12-15       Impact factor: 14.919

10.  68Ga-labeled PSMA-11 (68Ga-isoPROtrace-11) synthesized with ready to use kit: normal biodistribution and uptake characteristics of tumour lesions.

Authors:  Marina Muchnik Kurash; Ronit Gill; Maria Khairulin; Hanan Harbosh; Zohar Keidar
Journal:  Sci Rep       Date:  2020-02-20       Impact factor: 4.379

View more
  12 in total

1.  Dimeric FAPI with potential for tumor theranostics.

Authors:  Chunxia Qin; Yangmeihui Song; Weibo Cai; Xiaoli Lan
Journal:  Am J Nucl Med Mol Imaging       Date:  2021-12-15

2.  Nectin-4-targeted immunoSPECT/CT imaging and photothermal therapy of triple-negative breast cancer.

Authors:  Fuqiang Shao; Zhidi Pan; Yu Long; Jianwei Zhu; Xiaoli Lan; Ziyang Zhu; Kun Wang; Hao Ji; Ke Zhu; Wenyu Song; Yangmeihui Song; Xiangming Song; Yongkang Gai; Qingyao Liu; Chunxia Qin; Dawei Jiang
Journal:  J Nanobiotechnology       Date:  2022-05-25       Impact factor: 9.429

3.  Fatty acid-conjugated radiopharmaceuticals for fibroblast activation protein-targeted radiotherapy.

Authors:  Pu Zhang; Mengxin Xu; Jie Ding; Junyi Chen; Taiping Zhang; Li Huo; Zhibo Liu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-11-08       Impact factor: 10.057

Review 4.  Roles of the CXCL8-CXCR1/2 Axis in the Tumor Microenvironment and Immunotherapy.

Authors:  Zhi-Jian Han; Yang-Bing Li; Lu-Xi Yang; Hui-Juan Cheng; Xin Liu; Hao Chen
Journal:  Molecules       Date:  2021-12-27       Impact factor: 4.411

5.  Could Fibroblast Activation Protein (FAP)-Specific Radioligands Be Considered as Pan-Tumor Agents?

Authors:  Hessamoddin Roustaei; Zahra Kiamanesh; Emran Askari; Ramin Sadeghi; Kamran Aryana; Giorgio Treglia
Journal:  Contrast Media Mol Imaging       Date:  2022-02-22       Impact factor: 3.161

6.  Evans blue-modified radiolabeled fibroblast activation protein inhibitor as long-acting cancer therapeutics.

Authors:  Xuejun Wen; Pengfei Xu; Mengqi Shi; Jia Liu; Xinying Zeng; Yiren Zhang; Changrong Shi; Jingchao Li; Zhide Guo; Xianzhong Zhang; Pek-Lan Khong; Xiaoyuan Chen
Journal:  Theranostics       Date:  2022-01-01       Impact factor: 11.600

Review 7.  Pancreatic Ductal Adenocarcinoma: The Dawn of the Era of Nuclear Medicine?

Authors:  Christopher Montemagno; Shamir Cassim; Nicolas De Leiris; Jérôme Durivault; Marc Faraggi; Gilles Pagès
Journal:  Int J Mol Sci       Date:  2021-06-15       Impact factor: 5.923

8.  Radionuclides in Diagnostics and Therapy of Malignant Tumors: New Development.

Authors:  Vladimir Tolmachev; Anzhelika Vorobyeva
Journal:  Cancers (Basel)       Date:  2022-01-07       Impact factor: 6.639

9.  First-In-Human Results on the Biodistribution, Pharmacokinetics, and Dosimetry of [177Lu]Lu-DOTA.SA.FAPi and [177Lu]Lu-DOTAGA.(SA.FAPi)2.

Authors:  Sanjana Ballal; Madhav Prasad Yadav; Euy Sung Moon; Vasko S Kramer; Frank Roesch; Samta Kumari; Chandrasekhar Bal
Journal:  Pharmaceuticals (Basel)       Date:  2021-11-24

Review 10.  Bête Noire of Chemotherapy and Targeted Therapy: CAF-Mediated Resistance.

Authors:  Pradip De; Jennifer Aske; Raed Sulaiman; Nandini Dey
Journal:  Cancers (Basel)       Date:  2022-03-16       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.